AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32878566 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified if treated with any other intervention)
Number of subjects: 315
Study 32878604 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit fasting plasma glucose (FPG) variability
Number of subjects: 437
Study 32878614 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation and Environment Measure (post-PICU dissatisfaction assessment)
Number of subjects: 170
Study 32878614 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental support and participation-focused strategies with PICU-based rehabilitation services
Number of subjects: 170
Study 32878614 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver stress and functional performance
Number of subjects: 170
Study 32878766 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg combined with gemcitabine (1,000 mg/m2) and cisplatin
Number of subjects: 51
Study 32878766 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Number of subjects: 51
Study 32878766 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Number of subjects: 51
Study 32879034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-in-time vital signs information
Number of subjects: 284
Study 32879034 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vital sign information with static clinical data
Number of subjects: 284
Study 32879034 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 284
Study 32879326 — intervention group
Group type: EXPERIMENTAL
Intervention: Crolibulin (13-24 mg/m2)
Number of subjects: 11
Study 32879339 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire (score ≥ 3 of 8)
Number of subjects: 290
Study 32879339 — intervention group
Group type: COMPARATOR
Intervention: STOP-Bang questionnaire (score < 3 of 8)
Number of subjects: 290
Study 32879938 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation (7 biomarkers for type 1 diabetes, 24 biomarkers for type 2 diabetes)
Number of subjects: 456
Study 32879938 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation (6 biomarkers: CD5, CCL23, CST5, IL-10RB, PD-L1, TNFRSF9)
Number of subjects: 456
Study 32879938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers
Number of subjects: 456
Study 32879974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using VISITAG SURPOINT with specific targets (≥550 on anterior wall; ≥400 on posterior wall) and intertag distance (≤6 mm)
Number of subjects: 340
Study 32879974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 340
Study 32880091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate preoperative renal artery embolization (IPRAE)
Number of subjects: 145
Study 32880091 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPRAE)
Number of subjects: 145
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) + Treatment-as-Usual (TAU)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC) + Treatment-as-Usual (TAU)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) + Standard Maintenance (SM)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Whilst Intoxicated (DWI) programme + incarceration
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Problem-Solving (SPS) + Psychoeducation (PE)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT)
Number of subjects: 605
Study 32880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial Risk Management (PSRM)
Number of subjects: 605
Study 32880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg/day)
Number of subjects: 416
Study 32880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (250 to 300 mg/day)
Number of subjects: 416
Study 32880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (25 to 75 mg/day)
Number of subjects: 416
Study 32880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg/day)
Number of subjects: 416
Study 32880105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 416
Study 32881280 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis with therapy matched to ctDNA alterations (N=33 patients)
Number of subjects: 105
Study 32881280 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ctDNA maximum mutation allele frequency
Number of subjects: 105
Study 32881280 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 105
Study 32881280 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA and tissue genomic results
Number of subjects: 105
Study 32881586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment
Number of subjects: 0
Study 32881886 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (100 mg/kg single dose)
Number of subjects: 3
Study 32881886 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (100 mg/kg three times daily po X 6 weeks)
Number of subjects: 3
Study 32882243 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 risk assessment calculator
Number of subjects: 0
Study 32882243 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 parameters (BNP/NT-proBNP, 6MWD, FC)
Number of subjects: 0
Study 32882243 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 with missing variables (heart rate, SBP, eGFR)
Number of subjects: 0
Study 32882243 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2
Number of subjects: 0
Study 32882399 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker intake before exposure to loud noise (∼100 dB)
Number of subjects: 23
Study 32882399 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker intake before simulated diving (face immersion in cold water)
Number of subjects: 23
Study 32882958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health activities incorporated into pediatric well-child visits
Number of subjects: 0
Study 32882958 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pediatric well-child visits without oral health activities)
Number of subjects: 0
Study 32882978 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meals defined by dietary quality
Number of subjects: 0
Study 32882978 — intervention group
Group type: EXPERIMENTAL
Intervention: mReg scores
Number of subjects: 0
Study 32882978 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 0
Study 32883179 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition subtests for the Repeatable Battery for the Assessment of Neuropsychological Status
Number of subjects: 0
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 144
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training
Number of subjects: 144
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional interventions
Number of subjects: 144
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping activity
Number of subjects: 144
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and baseline function
Number of subjects: 144
Study 32883192 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with smallest gains
Number of subjects: 144
Study 32883248 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative suggestions for improving HIV prevention efforts
Number of subjects: 288
Study 32883297 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES of the vastus lateralis and rectus femoris during stance
Number of subjects: 1
Study 32883297 — intervention group
Group type: COMPARATOR
Intervention: Current Ankle-Foot Orthosis (AFO)
Number of subjects: 1
Study 32883297 — intervention group
Group type: COMPARATOR
Intervention: Unassisted Exoskeleton
Number of subjects: 1
Study 32883297 — intervention group
Group type: COMPARATOR
Intervention: NMES of the vastus lateralis
Number of subjects: 1
Study 32883677 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 0
Study 32883728 — intervention group
Group type: EXPERIMENTAL
Intervention: CT index test in the neutral position
Number of subjects: 0
Study 32883728 — intervention group
Group type: EXPERIMENTAL
Intervention: CT index test with stress manoeuvres (external rotation)
Number of subjects: 0
Study 32883728 — intervention group
Group type: EXPERIMENTAL
Intervention: CT index test with stress manoeuvres (dorsiflexion)
Number of subjects: 0
Study 32883728 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot and Ankle Ability Measure questionnaire
Number of subjects: 0
Study 32883871 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-28ζ CAR T-cell therapy
Number of subjects: 52
Study 32883871 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with formal echocardiograms and cardiac biomarkers (troponin and proBNP)
Number of subjects: 52
Study 32884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0
Study 32884017 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study 32884151 — intervention group
Group type: EXPERIMENTAL
Intervention: AAVrh8 gene therapy injected into the thalamus and deep cerebellar nuclei
Number of subjects: 0
Study 32884151 — intervention group
Group type: EXPERIMENTAL
Intervention: AAVrh8 gene therapy
Number of subjects: 0
Study 32884151 — intervention group
Group type: COMPARATOR
Intervention: Untreated cats
Number of subjects: 0
Study 32884231 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Latanoprost 0.005%
Number of subjects: 36
Study 32884231 — intervention group
Group type: COMPARATOR
Intervention: Topical Timolol Maleate 0.5%
Number of subjects: 36
Study 32884828 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A) using 2-mL dilution (500 U/2-mL)
Number of subjects: 0
Study 32885090 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Coaching (HWC) - a 12-month web-based intervention
Number of subjects: 0
Study 32885091 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric high-GI Mediterranean-style healthy eating pattern (MED-HEP) for 12 weeks
Number of subjects: 0
Study 32885091 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric low-GI Mediterranean-style healthy eating pattern (MED-HEP) for 12 weeks
Number of subjects: 0
Study 32885133 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM-enriched bovine milk beverage
Number of subjects: 0
Study 32885133 — intervention group
Group type: COMPARATOR
Intervention: Comparator beverage (nonfat dairy powder, coconut and palm oils, and soy phospholipids)
Number of subjects: 0
Study 32885187 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary geriatric assessment in the ED setting
Number of subjects: 0
Study 32885188 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth intervention implementing the WHO Safe Childbirth Checklist; details on dosage and duration not available.
Number of subjects: 0
Study 32885188 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth intervention; details on dosage and duration not available.
Number of subjects: 0
Study 32885198 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-Minds-Strong Bodies (PM-SB) intervention consisting of cognitive behavior therapy and exercise training sessions delivered over 6 months.
Number of subjects: 30
Study 32885198 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-SB intervention
Number of subjects: 30
Study 32885214 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI) implementation
Number of subjects: 21
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based clinical decision support tools that integrate into the workflow and do not extend visit time
Number of subjects: 52
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources that respond to family's needs
Number of subjects: 52
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal delivery options for family resources
Number of subjects: 52
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing childhood obesity while balancing competing demands
Number of subjects: 52
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient care rather than documentation and establishing sustainability plans
Number of subjects: 52
Study 32885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple training methods that incorporate performance feedback
Number of subjects: 52
Study 32885217 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores on CFIR organizational characteristics (e.g., organizational readiness, implementation climate, organizational culture, innovation fit)
Number of subjects: 34
Study 32885217 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering health programs
Number of subjects: 34
Study 32885217 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational factors for health programming
Number of subjects: 34
Study 32885241 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic onycholysis (ONY)
Number of subjects: 87
Study 32885241 — intervention group
Group type: COMPARATOR
Intervention: PsA group
Number of subjects: 87
Study 32885241 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls (CTRL)
Number of subjects: 87
Study 32885254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-infrared fibre evanescent wave spectroscopy
Number of subjects: 402
Study 32885664 — intervention group
Group type: EXPERIMENTAL
Intervention: DNMT3A knockout in cardiomyocytes
Number of subjects: 0
Study 32885664 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 0
Study 32885736 — intervention group
Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device
Number of subjects: 60
Study 32885736 — intervention group
Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device (without considering bailout stenting as TLR)
Number of subjects: 60
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake of polyunsaturated fat
Number of subjects: 93
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake of fiber from grains
Number of subjects: 93
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk exclusivity
Number of subjects: 93
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of direct breastfeeding per day
Number of subjects: 93
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fiber intake from grains
Number of subjects: 93
Study 32886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fiber consumption
Number of subjects: 93
Study 32886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 0.5 g every 6 hours
Number of subjects: 10
Study 32886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 1 g every 6 hours
Number of subjects: 10
Study 32886753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (15-21 mg/kg cumulative doses, administered as 1 to 5 once-weekly subcutaneous infusions)
Number of subjects: 66
Study 32886753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (15-20 mg/kg single doses)
Number of subjects: 66
Study 32886753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 66
Study 32886914 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels measured daily in the first 3 days post-aSAH
Number of subjects: 132
Study 32886914 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels in infection-free patients
Number of subjects: 132
Study 32886914 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels post-DCI
Number of subjects: 132
Study 32887239 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions, attitudes, and behaviors regarding obesity management among people with obesity
Number of subjects: 1500
Study 32887239 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals' perceptions and attitudes towards obesity management
Number of subjects: 1500
Study 32887588 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit HbA
Number of subjects: 420
Study 32887637 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Newsletter intervention (8 newsletters)
Number of subjects: 136
Study 32887637 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents from other municipalities)
Number of subjects: 136
Study 32887722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 600 mg (3 weeks on, 1 week off) plus Fulvestrant 500 mg
Number of subjects: 70
Study 32887722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg plus Buparlisib 30 mg plus Fulvestrant 500 mg
Number of subjects: 70
Study 32887722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg plus Alpelisib (no RP2D determined)
Number of subjects: 70
Study 32887722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus Fulvestrant (general)
Number of subjects: 70
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BMP-7
Number of subjects: 708
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin
Number of subjects: 708
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum DKK-1
Number of subjects: 708
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BMP-7 in active disease (ASDAS with CRP ≥1.3)
Number of subjects: 708
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BMP-7 with TNF inhibitor (TNFi) use
Number of subjects: 708
Study 32888036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin change
Number of subjects: 708
Study 32888112 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME-CoV rule (criteria for hospitalization)
Number of subjects: 51
Study 32888407 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 344
Study 32888452 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus obinutuzumab
Number of subjects: 432
Study 32888452 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab
Number of subjects: 432
Study 32888723 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with complex family planning specialists
Number of subjects: 97
Study 32888723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive methods (intrauterine device and contraceptive implant)
Number of subjects: 97
Study 32889146 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-target HCC panel (3 MDMs: HOXA1, EMX1, TSPYL5; B3GALT6; 2 protein markers: AFP and AFP-L3)
Number of subjects: 135
Study 32889146 — intervention group
Group type: COMPARATOR
Intervention: GALAD score
Number of subjects: 135
Study 32889146 — intervention group
Group type: COMPARATOR
Intervention: AFP ≥7.32 ng/mL
Number of subjects: 135
Study 32889146 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-target HCC panel
Number of subjects: 135
Study 32889146 — intervention group
Group type: COMPARATOR
Intervention: AFP alone
Number of subjects: 135
Study 32889525 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with weight loss <5%
Number of subjects: 2071
Study 32889525 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese women with weight loss ≥5%
Number of subjects: 2071
Study 32889525 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obese men
Number of subjects: 2071
Study 32889812 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 expression in squamous cell carcinomas (SCCs)
Number of subjects: 26
Study 32889812 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 expression in basal cell carcinomas
Number of subjects: 26
Study 32889812 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 expression in precancerous lesions
Number of subjects: 26
Study 32889812 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal skin COX-2 expression
Number of subjects: 26
Study 32889866 — intervention group
Group type: EXPERIMENTAL
Intervention: PD with PVR
Number of subjects: 840
Study 32889978 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume management strategies (specific interventions not detailed)
Number of subjects: 0
Study 32889978 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel methods of assessing and restoring extracellular fluid volume
Number of subjects: 0
Study 32889978 — intervention group
Group type: EXPERIMENTAL
Intervention: Local protocols and programmes for volume management
Number of subjects: 0
Study 32890108 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 10
Study 32890324 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) performed 2 weeks after initial TACE treatment.
Number of subjects: 69
Study 32890324 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 69
Study 32890609 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface imaging with verbal instruction and gating
Number of subjects: 10
Study 32890609 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom studies
Number of subjects: 10
Study 32891132 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen treatment
Number of subjects: 20
Study 32891132 — intervention group
Group type: EXPERIMENTAL
Intervention: FACS analysis
Number of subjects: 20
Study 32891132 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMI correlation
Number of subjects: 20
Study 32891319 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port access laparoscopic radical hysterectomy (SPA LRH)
Number of subjects: 59
Study 32891400 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (platelet count <150 × 10^9/L)
Number of subjects: 0
Study 32891400 — intervention group
Group type: COMPARATOR
Intervention: Normal platelet count (≥150 × 10^9/L)
Number of subjects: 0